secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0000950170-25-043828
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva reports 2024 net loss of $65.4M; cash $185.4M; autoimmune data expected H1 2025
--------------------------------------------------------------------------------

- Net loss of $65.4M in 2024 vs net income of $28.7M in 2023; no collaboration revenue vs $32.9M prior year.
- Cash, cash equivalents and investments $185.4M at Dec 31, 2024, expected to fund operations through end of 2026.
- Initial data from AlloNK (AB-101) in autoimmune indications (SLE/LN, RA) expected in H1 2025.
- Appointed Dan Baker to Board and added SVP-level leadership in Regulatory, Clinical Ops, and Biometrics.
- Updated Phase 1/2 NHL trial data for AlloNK + rituximab showing durability to be presented at 2025 medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/0000950170-25-043828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/artv-20250324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-043828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer